"Do not take my word for it but all NNLX tech is not new and is garbage. I don't know why the word of aliases on a MB claiming any of the tech was uniquely innovative became gospel? So the CEO must be an idiot for not being capable of taking such great innovations to market misses the deep subject."
if the tech is awesome and he hasn't done much with it, its obvious he's incompetent. If it has any worth and he hasn't done much with it, what kind of genius is he ?
Now what some will point to is why is the Faro(s) there then if there is nothing of value ?
Also, look how awesome they talk about their stuff....all that awesomeness and nothing meaningful....either this is just talking it up or they don't have a clue how to take something special anywhere to make the shareholders proud ? You decide ?
NanoLogix technology provides live-cell rapid detection and identification dramatically faster than Flow Cytometry and traditional Petri culture methods. Additionally, in contrast to other fast methods such as Polymerase Chain Reaction (PCR), our technology does not require large investments in equipment or personnel training. Our N-Assay and new Rapid Virus Assay technologies are simple, easy to use and portable. They provide a more accurate, cost-effective alternative to PCR and Flow Cytometry.
Quantitative, Live-Cell and Rapid Virus Results
In the past decades, DNA analysis has emerged as a popular, yet expensive, trend to speed up microorganism diagnostics. Other disadvantages of this type of analysis (also known as PCR) include a failure of the technology to return live-cell results. Instead, these tests are only able to detect for the presence of the organism in a sample. Technicians using PCR are unable to determine the viability of the microorganisms from these results.
Results using NanoLogix technology, by contrast, are fast and can detect whether or not a microorganism found in the sample is alive, and therefore a viable health threat. This distinction between live and dead cells is a crucial requirement in the identification of pathogenic microorganisms. It is the reason many laboratories continue to insist on live-cell results, despite the longer wait for results. Benefits to Rapid, Live-Cell Microorganism Detection
IN THE CLINIC:
Antibiotic treatment is more effective when an infectious disease is identified at an early stage. The spread of infectious disease as well as growth of antibiotic resistance can be reduced by earlier intervention.
IN RAPID VIRUS DETECTION
Our new Rapid Virus Assay provides the ability to detect essentially any virus in approximately 1 hour or less. This was developed based up the need for rapid detection of COVID 19 and is in patent-pending status. IN PHARMACEUTICAL R&D
Rapid detection of live-cell microorganisms increases the speed of pharmaceutical R&D, including faster product development and more effective countermeasures for pathogenic bacteria when they are detected. IN BIODEFENSE
Our rapid tests give combat theaters and homeland security operations the ability to detect the presence of specific pathogenic bacteria closer to the epicenter of release. Site decontamination teams can identify surface samples faster, potentially aiding the field process.
IN FOOD, BEVERAGE AND COSMETIC MANUFACTURING
Rapid detection of live-cell microbial contamination minimizes the impact of contaminated products. Our rapid tests pre-empt expensive recalls and protect corporate reputations. Potential government-mandated “microbiology holds,” which cause delays in product shipment, can be averted and the speed of new product development can be increased.
News 
Market Data 
Discover 
